These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 14605589)

  • 21. [Enalapril and irbesartan in treatment of patients with arterial hypertension].
    Tashchuk VK; Ilashchuk TO
    Lik Sprava; 2002; (3-4):114-6. PubMed ID: 12145874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Irbesartan: a new possibility in the treatment of hypertension].
    Rapi J
    Orv Hetil; 2002 May; 143(21):1187-92. PubMed ID: 12073539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical profiles of new angiotensin II receptor blockers: telmisartan, olmesartan medoxomil, and irbesartan].
    Ishii M
    Nihon Rinsho; 2004 Jan; 62(1):193-202. PubMed ID: 14737853
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single nucleotide polymorphisms in the apolipoprotein B and low density lipoprotein receptor genes affect response to antihypertensive treatment.
    Liljedahl U; Lind L; Kurland L; Berglund L; Kahan T; Syvänen AC
    BMC Cardiovasc Disord; 2004 Sep; 4(1):16. PubMed ID: 15453913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [IRMA-pRAcs: irbesartan in the treatment of microalbuminuria and proteinuria in patients with type 2 diabetes and hypertension-prospective observational study involving 38,016 patients in the general practice setting].
    Lehnert H; Bramlage P; Pittrow D; Kirch W
    MMW Fortschr Med; 2003 Oct; 145 Suppl 3():81-7. PubMed ID: 15490772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of angiotensin II blockade on cardiac hypertrophy and remodelling: a review.
    Dahlöf B
    J Hum Hypertens; 1995 Nov; 9 Suppl 5():S37-44. PubMed ID: 8583480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pharmacogenetics and pharmacogenomics. Searching for individual antihypertensive therapy concepts].
    Brand E
    MMW Fortschr Med; 2003 May; 145(19):43-4. PubMed ID: 12813978
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacogenetics of antihypertensive drug responses.
    Schwartz GL; Turner ST
    Am J Pharmacogenomics; 2004; 4(3):151-60. PubMed ID: 15174896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Observational study of blood pressure control and microalbuminuria in type 2 diabetics on Irbesartan or Irbesartan/HCTZ].
    Schmieder RE; Krekler M
    MMW Fortschr Med; 2005 Aug; 147(31-32):43. PubMed ID: 16128197
    [No Abstract]   [Full Text] [Related]  

  • 30. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
    Parving HH; Lehnert H; Bröchner-Mortensen J; Gomis R; Andersen S; Arner P;
    N Engl J Med; 2001 Sep; 345(12):870-8. PubMed ID: 11565519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
    Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ; Lewis JB
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Irbesartan achieves consistent and effective use over 1 year.
    Cardiovasc J S Afr; 2001; 12(2):126. PubMed ID: 11474701
    [No Abstract]   [Full Text] [Related]  

  • 34. [Irbesartan--current trends in the management of hypertension].
    Dtsch Med Wochenschr; 1998 Feb; 123(8 Suppl):1-4. PubMed ID: 9531920
    [No Abstract]   [Full Text] [Related]  

  • 35. [Renin-angiotensin system blockade. What can be expected from angiotensin II antagonists?].
    Waeber B; Nussberger J; Brunner H
    Rev Prat; 1992 Oct; 42(16):2066-8. PubMed ID: 1485114
    [No Abstract]   [Full Text] [Related]  

  • 36. Drug interactions with irbesartan.
    Marino MR; Vachharajani NN
    Clin Pharmacokinet; 2001; 40(8):605-14. PubMed ID: 11523726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Irbesartan prevents the progression of kidney disease or death in patients with type 2 diabetes and high blood pressure.
    Cardiovasc J S Afr; 2001; 12(4):240-1. PubMed ID: 11766617
    [No Abstract]   [Full Text] [Related]  

  • 38. A new class of antihypertensive therapy: angiotensin II receptor antagonists.
    Ellis ML; Patterson JH
    Pharmacotherapy; 1996; 16(5):849-60. PubMed ID: 8888079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Efficacy-safety relationship of AT1 angiotensin II receptor antagonists: current data].
    Paoletti V; Di Veroli C; Pugliese M; Cammarella I; Cavina G; Turchetti P; Mammarella A
    Clin Ter; 2002; 153(1):61-4. PubMed ID: 11963637
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients.
    Gradman AH; Schmieder RE; Lins RL; Nussberger J; Chiang Y; Bedigian MP
    Circulation; 2005 Mar; 111(8):1012-8. PubMed ID: 15723979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.